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Commentary 
Despite substantial advances in the management of cardiovascular disease, it 
remains a major cause of morbidity and mortality worldwide [1]. Globally, 
cardiovascular disease is expected to account for over 23 million deaths by the year 
2030, mostly attributable to an increasing incidence in low and middle income 
countries [2].  Within the World Health Organisation European Region, 
cardiovascular disease accounts for over 4 million deaths per year. However, this rate 
varies considerably between European countries with evidence from observational 
databases to suggest that mortality rates from cardiovascular disease are higher in 
countries of Central and Eastern Europe, Central Asia, Finland and Malta.  
 
Clinical registries are observational databases which focus on a clinical condition, 
treatment or population [3]. Data are collected systematically with broad inclusion 
and limited exclusion criteria. The role of clinical registries is to capture 
generalisable and representative information to, therefore, provide insights into 
patient characteristics, patterns of care and outcomes IRUCUHDOZRUOG¶SRSXODWLRQV
and clinical settings. While randomised control trials (RCTs) are the gold standard 
for determining treatment efficacy, that is, in a controlled clinical environment, 
clinical registries play an important role in contributing to the evidence representing 
care and outcomes in the environments in which healthcare is practiced. Both type of 
studies are complementary for the assessment of the safety of interventions or 
medical therapies. Clinical registries, in particular, are powerful resources for 
studying long term outcomes and temporal trends, identifying novel associations and 
monitoring inequalities in care and outcomes which cannot always be achieved in a 
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randomized controlled trial setting due to ethical constraints as well as their cost. 
Cardiovascular registries are increasingly used for comparative effectiveness research, 
a priority area for the Institute of Medicine [4]. Through collecting and reporting real 
world data, clinical registries have a central role in cardiovascular quality 
improvement as well as research.  
 
To date, clinical registries of cardiovascular disease have been predominantly 
founded in high income and Western countries. The Myocardial Ischaemia National 
Audit Project (MINAP) is a clinical registry of acute coronary syndrome 
hospitalisations in England and Wales [5]. It was started in 2000 and has 
information pertaining to over 1.2 million events (Figure 1). Participation in the 
registry is near-universal and, in recent years, has been mandated by the Department 
of Health. The clinical registry collects information that characterises the pre-
hospital and hospital course of patients experiencing an acute coronary syndrome, 
with the number of data fields expanding steadily since inception. Data are self-
reported by hospital-based clinicians or clerks into standardised electronic forms, 
and uploaded to central servers. The MINAP data application has error-checking 
routines, including range and consistency checks. An annual data validation exercise 
requires participating hospitals to re-enter 20 data items from the medical records of 
20 randomly selected patients. Other countries with cardiovascular registries include 
Sweden (Register of Information and Knowledge about Swedish Heart Intensive care 
Admissions, SWEDEHEART/RIKSHIA) [6], France (French Registry on Acute ST-
elevation and non ST-elevation Myocardial Infarction, FAST-MI) [7] and the United 
States (Acute Coronary Treatment and Intervention Outcomes Network Registry ² 
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Get With The Guidelines, ACTION Registry-GWTG)/National Cardiovascular Data 
Registry, NCDR) [8].  
However, only a minority of countries have clinical registries of cardiovascular 
disease, and not all are mandatory which can lead to potential participation bias. A 
recent review of the literature suggested that most central and eastern European 
countries did not have published acute coronary syndrome care and outcomes data 
[9]. Of those that did, there was evidence for wide variation in emergency strategies 
for the reperfusion of ST-segment elevation myocardial infarction (STEMI) [10]. 
Moreover, a significant East-West gap across European countries was evident in 
recent comparative studies of aggregate national and regional registry survey data 
despite recent improvements in the quality of care and increased rates of reperfusion 
strategies for STEMI [11, 12]. Explanations for geographical variations in emergency 
strategies and mortality rates are not always clear. Many studies have focused on 
differences in social, economic, cultural and clinical risk factors. Indeed in the 
MONICA study improvements in mortality rates during a 10-year period showed a 
greater relationship with a decline in pre-hospital mortality rates [13]. Beyond the 
quality of care provided in hospitals, differences in pre-hospital logistics, 
management and time delays strongly influence patients' outcome. This is 
particularly true for the Central and Eastern European countries [12, 14, 15]. 
Differences in social and economic factors play a crucial role in risk profile, acute 
coronary care and secondary prevention and need to be considered when comparing 
East-West patient populations. In 2010, the International Survey of Acute Coronary 
Syndromes in Transitional Countries (ISACS-TC; ClinicalTrials.gov: NCT01218776) 
was launched, aiming to collect real world registry data concerning the quality of care 
and clinical outcomes of patients hospitalised across 11 Central and Eastern 
European countries with acute coronary syndrome [16]. The ISACS-TC is both a 
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retrospective (over a one year period) and prospective registry. Currently there are 
29 tertiary healthcare services providing advanced medical investigation and 
treatment including percutaneous coronary intervention (PCI) and/or cardiac 
surgery, and 28 secondary healthcare services providing intensive coronary care. 
Participating hospitals are instructed to record data from consecutive hospital 
admissions and to register these data into standardised electronic charts on an 
internet-based database system before being uploaded to the data bank of the 
international coordinating centre [16].  
 
To date this international clinical registry has revealed substantial opportunities for 
healthcare improvement among patients with acute STEMI (as reflected in long 
times to reperfusion and high 30 day mortality rates), and reported the efficiency of 
early ǃEORFNDGHIROORZLQJDFXWHFRURQDU\V\QGURPHDVVRFLDWHGZLWKLPSURYHGOHIW
ventricular systolic function and higher in-hospital survival rates)[14, 17].  A recent 
study from the ISACS-TC registry reviewed current practice in antithrombotic 
therapy and reported that STEMI patients who fail to receive any reperfusion therapy 
benefit in terms of survival from unfractioned heparin - clopidogrel combination 
therapy without significant increases in risk of bleeding as compared to combined 
enoxaparin and clopidogrel therapy [18]. These findings are of note if we consider 
that non-reperfused STEMI patients are a major concern despite advances in 
emergency management. Moreover, recommendations in current guidelines for non-
reperfused STEMI patients are based mostly on expert opinions rather than on 
evidence from clinical trials or clinical registries.  
 
Whilst there are several reports of between country comparisons of acute myocardial 
infarction care and outcomes, typically these have either compared high performing 
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countries with each other,[19-21] eastern countries with each other,[14, 16] or used 
aggregated data[11, 22, 23] to compare many countries. There are limited 
contemporary comparisons of care for acute myocardial infarction between eastern 
and western European countries which have used patient-level data derived from a 
range of clinical registries [10]. International comparisons contextualise the quality 
of care provided in different countries and highlight opportunities for improvement. 
Moreover, variation between hospitals in quality of care and clinical outcomes 
provides useful insight into the performance of national health systems. For example, 
comparative research has shown that specific aspects of cardiovascular care are 
better and vary less between hospitals in Sweden than in the United Kingdom and 
that this is associated with many potentially avoidable deaths in the United Kingdom 
[19, 20].  
 
As such we are left with a gap in the knowledge base about how eastern European 
countries directly compare with Western countries in their management of acute 
myocardial infarction. A concerted effort is needed to establish an international 
research consortium that will enable harmonised cardiovascular data collection and 
standardised reporting across Eastern and Western European countries. Such a 
research µDUF¶ZRXOGHQDEOHWDUJHWHGTXDOLW\LPSURYHPHQWWRUHGXFHXQZDUUDQWHG
variation in mortality across Europe. The implementation of international quality 
indicators for the evaluation and comparison of achievement of standards of acute 
cardiovascular care is a critical role that clinical registries will soon need to adopt.  
In addition, there is huge scope for novel research ± using individual patient data 
meta-analyses to study rare cardiovascular events, repurposing clinical data for the 
design of multinational studies and the conduct of efficient registry-based 
randomised controlled trials [24].  
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It is clear that a new approach to the international study of cardiovascular care is 
justified. Clinical registries are not only important to assess the effectiveness and 
safety of health interventions but are critical for the assessment of the quality of 
healthcare systems and more so, for quality improvement. For this reason, 
promotion of comparable national clinical registries, mandatory rather than 
volunteer, using similar definitions for diseases, interventions and outcomes should 
be fostered across Europe [25]. This is an urgent need for Eastern European 
countries, where there may be a greater need of cyclical clinical evaluation for 
research and particularly for identification of targets for quality improvement 
initiatives.  
 
FIGURE LEGEND 
Figure 1: Random sample of acute coronary syndrome events in England and Wales 
from the Myocardial Ischaemic National Audit Project clinical registry, 2003-2013 
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